Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Johnetta Blakely
Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Related publications
Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Phase 1b Study of Orteronel in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic Breast Cancer
Investigational New Drugs
Oncology
Pharmacology
Quantitative ER and PgR Assessment as Predictors of Benefit From Lapatinib in Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Phase I Trial of Exemestane in Combination With Metformin and Rosiglitazone in Nondiabetic Obese Postmenopausal Women With Hormone Receptor–positive Metastatic Breast Cancer
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
Frontiers in Oncology
Cancer Research
Oncology
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer
JAMA Oncology
Cancer Research
Oncology
A Randomized Trial of Combination Anastrozole Plus Gefitinib and of Combination Fulvestrant Plus Gefitinib in the Treatment of Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Breast Cancer Research and Treatment
Cancer Research
Oncology
TBCRC 002: A Phase II, Randomized, Open-Label Trial of Preoperative Letrozole With or Without Bevacizumab in Postmenopausal Women With Newly Diagnosed Stage 2/3 Hormone Receptor-Positive and HER2-negative Breast Cancer
Breast Cancer Research
Cancer Research
Oncology
